Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination

Ashrani, Aneel A.; Crusan, Daniel J.; Petterson, Tanya M.; Bailey, Kent R.; Heit, John A.

doi:10.1001/jamainternmed.2021.6352

Cited by 12 publications

(15 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With regard to factors associated with increased risk of TE in the Covid-19 vaccine group, we found age as an important risk factor, adding a 5% increase risk for each year of age older, and we found no difference in risk between sexes. These findings are contrary to previous observations that found increased risk of a specific type of thrombosis (CVST) in younger women [27] . Most patients with TE in our series had classical risk factors (cancer, previous VTE, thrombophilia or recent surgery) and no manifestation of VITT, suggesting that events found have a different mechanism than the one described for VITT or no relation at all with the vaccines.…”

Section: Discussioncontrasting

confidence: 99%

Thrombotic events following Covid-19 vaccines compared to Influenza vaccines

Vallone

Falcón

Castro

et al. 2022

European Journal of Internal Medicine

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 99%

Thrombotic events following Covid-19 vaccines compared to Influenza vaccines

Vallone

Falcón

Castro

et al. 2022

European Journal of Internal Medicine

View full text Add to dashboard Cite

“…Production of soluble spike protein was caused by splicing events. Soluble spike protein has been found to cause an inflammatory response in endothelial cells [ 12 , 94 ]. A population-based cohort study estimated the risk of CVST after Ad26.COV2.S [ 94 ].…”

Section: Discussionmentioning

confidence: 99%

Investigation of Neurological Complications after COVID-19 Vaccination: Report of the Clinical Scenarios and Review of the Literature

Chen

Shang

et al. 2023

Vaccines

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), broke out in 2019 and became a pandemic in 2020. Since then, vaccines have been approved to prevent severe illness. However, vaccines are associated with the risk of neurological complications ranging from mild to severe. Severe complications such as vaccine-induced immune thrombotic thrombocytopenia (VITT) associated with acute ischaemic stroke have been reported as rare complications post-COVID-19 vaccination. During the pandemic era, VITT evaluation is needed in cases with a history of vaccination within the last month prior to the event. Cerebral venous sinus thrombosis (CVST) should be suspected in patients following immunization with persistent headaches who are unresponsive to analgesics. In this article, we investigated neurological complications after COVID-19 vaccination and provided more subsequent related clinical studies of accurate diagnosis, pathophysiological mechanisms, incidence, outcome, and management.

show abstract

Section: Discussionmentioning

confidence: 99%

“…8 Other reports have indicated that there was an increase in CVST incidence following the post-COVID-19 AstraZeneca and Johnson & Johnson/Janssen vaccination when compared to pre-pandemic incidence. 2,9 The increase in incidence could be explained by pathophysiological changes thought to occur in VITT. CVST post-COVID-19 vaccination arises as a consequence of VITT.…”

Section: Discussionmentioning

confidence: 99%

Cerebral Venous Sinus Thrombosis Following COVID-19 Vaccination: A Systematic Review

Jaiswal

Nepal

Dijamco

et al. 2022

J Prim Care Community Health

View full text Add to dashboard Cite

Introduction: COVID-19 vaccines became available after being carefully monitored in clinical trials with safety and efficacy on the human body. However, a few recipients developed unusual side effects, including cerebral venous sinus thrombosis (CVST). We aim to systematically review the baseline features, clinical characteristics, treatment, and outcomes in patients developing CVST post-COVID-19 vaccination. Methods: This study was conducted according to the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analysis) 2020 guideline. Investigators independently searched PubMed, Embase, and Google Scholar for English language articles published from inception up until September 10, 2021, reporting the incidence of CVST post-COVID-19 vaccines. We analyzed CVST patients’ baseline data, type of vaccines, clinical findings, treatment, and outcomes. Our systematic review process yielded patient-level data. Result: The final analysis included 25 studies that identified 80 patients who developed CVST after the COVID-19 vaccination. Of the 80 CVST cases, 31 (39.24%) patients died. There was no significant relationship between mortality and age ( P = .733), sex ( P = .095), vaccine type ( P = .798), platelet count ( P = .93), and comorbidities such as hypertension ( P = .734) and diabetes mellitus ( P = .758). However, mortality was associated with the duration of onset of CVST symptoms after vaccination ( P = .022). Patients with CVST post-COVID-19 vaccination were more likely to survive if treated with an anticoagulant ( P = .039). Patients who developed intracranial hemorrhage ( P = .012) or thrombosis in the cortical vein ( P = .021) were more likely to die. Conclusion: COVID-19 vaccine-associated CVST is associated with high mortality rate. Timely diagnosis and management can be lifesaving for patients.

show abstract

Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination

Cited by 12 publications

References 5 publications

Thrombotic events following Covid-19 vaccines compared to Influenza vaccines

Thrombotic events following Covid-19 vaccines compared to Influenza vaccines

Investigation of Neurological Complications after COVID-19 Vaccination: Report of the Clinical Scenarios and Review of the Literature

Cerebral Venous Sinus Thrombosis Following COVID-19 Vaccination: A Systematic Review

Contact Info

Product

Resources

About